Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Francesco Rodeghiero · SciRah

Researcher profile · Semantic Scholar

Francesco Rodeghiero

Share profile

Francesco Rodeghiero — researcher profile on SciRah

h-index: 8
Works: 17
Citations: 554

Most-cited papers

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
T. Barbui, A. Vannucchi, V. Buxhofer-Ausch, V. De Stefano +14 more
2015Blood Cancer Journal256 citations Open access
Semantic Scholar
Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.
C. Schiavotto, M. Ruggeri, Francesco Rodeghiero
1993Haematologica95 citations
Semantic Scholar
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
C. Broome, V. McDonald, Yoshitaka Miyakawa, M. Carpenedo +9 more
2023The Lancet87 citations Open access
Semantic Scholar
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
P. Tacchetti, L. Pantani, F. Patriarca, M. Petrucci +93 more
2020The Lancet Haematology44 citations
Semantic Scholar
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
T. Barbui, A. Carobbio, Juergen Thiele, N. Gangat +21 more
2023Blood Cancer Journal23 citations Open access
Semantic Scholar
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
Bianca Rocca, A. Tosetto, G. Petrucci, Elena Rossi +25 more
2024American journal of hematology/oncology20 citations Open access
Semantic Scholar
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
M. Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, V. De Stefano +36 more
2024Blood Advances15 citations Open access
Semantic Scholar
Prognostic Impact of C-Kit Mutations in Core Binding Factor-Leukemia.
R. Cairoli, A. Beghini, G. Nadali, F. Elice +10 more
20048 citations
Semantic Scholar
The clinical significance of the antiplatelet antibody test based on results for 265 thrombocytopenic patients.
A. Tosetto, M. Ruggeri, Corrado Schiavotto, G. Pellizzari +1 more
1993Haematologica5 citations
Semantic Scholar
Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries
Guillaume Moulis, Frederick Chen, G. Carli, W. Ghanima +18 more
2025Haematologica2 citations Open access
Semantic Scholar
Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
C. Broome, V. McDonald, Yoshitaka Miyakawa, M. Carpenedo +10 more
2023Blood2 citations Open access
Semantic Scholar
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial
Nichola Cooper, C. Broome, Yoshitaka Miyakawa, V. McDonald +16 more
2026American journal of hematology/oncology0 citations Open access
Semantic Scholar
OC 25.2 Time to Achieve Platelet Count Response After Intravenous Efgartigimod in Adults With Primary Immune Thrombocytopenia in a Phase 3, Multicenter, Double-blinded, Placebo-controlled, Randomized Clinical Trial (ADVANCE IV) and Its Open-Label Extension Study (ADVANCE IV+)
Yoshitaka Miyakawa, C. Broome, Monica Carpenedo, Blanca González Sánchez +12 more
2026Research and Practice in Thrombosis and Haemostasis0 citations Open access
Semantic Scholar
Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study
C. Broome, Yoshitaka Miyakawa, Monica Carpenedo, H. Al-Samkari +3 more
2026Therapeutic Advances in Hematology0 citations Open access
Semantic Scholar
Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)
Monica Carpenedo, C. Broome, Blanca Sánchez González, V. McDonald +12 more
2025Blood0 citations
Semantic Scholar
A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders. Authors' reply
E. Albiero, M. Bernardi, D. Madeo, M. Ruggeri +1 more
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Broome×6
Invite
C. Broome — researcher profile on SciRah
V. McDonald×6
Invite
V. McDonald — researcher profile on SciRah
Yoshitaka Miyakawa×6
Invite
Yoshitaka Miyakawa — researcher profile on SciRah
H. Al-Samkari×6
Invite
H. Al-Samkari — researcher profile on SciRah

×6

Invite

J. Ayguasanosa — researcher profile on SciRah

Invite

K. De Beuf — researcher profile on SciRah

Invite

Marc Michel — researcher profile on SciRah

Adrian C. Newland×4

Invite

Adrian C. Newland — researcher profile on SciRah

Filip Matthijssens×4

Invite

Filip Matthijssens — researcher profile on SciRah

A. Vannucchi×3

Invite

A. Vannucchi — researcher profile on SciRah

V. De Stefano×3

Invite

V. De Stefano — researcher profile on SciRah

Invite

M. Ruggeri — researcher profile on SciRah